Skip to main content

AMERICAN BIO MEDICA CORP Value Stock - Dividend - Research Selection


ISIN: US0246001087, WKN: 912562

Market price date: 26.05.2021
Market price: 0,06 USD

AMERICAN BIO MEDICA CORP Fundamental data and company key figures of the share

Annual reports in USD
Key figures 24-04-2021
Cash flow
Net operating cash flow -483.000
Capital Expenditures -4.000
Free cash flow -487.000
Balance sheet
Total Equity -1.260.000
Liabilities & Shareholders equity 1.930.000
Income statement
Net income -796.000
Eps (diluted) -0,020
Diluted shares outstanding 35.560.000
Net sales/revenue 4.150.000

Fundamental ratios calculated on: 26-05-2021

Key figures 26-05-2021
Cash flow
P/C -4,42
P/FC -4,38
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization2.133.600,00 USD
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

American Bio Medica Corporation develops, manufactures and sells immunoassay tests, primarily for the immediate, point of collection testing (POCT) for drugs of abuse (DOA) in urine and oral fluids. The Company's DOA POCT products offer employers, law enforcement, government, healthcare and education professionals to identify illicit drug use. In addition to the manufacture and sale of DOA POCT products, the Company provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. Its Rapid Drug Screen (RDS) is a POCT product that detects the presence or absence of 2 to 10 DOA simultaneously in a single urine specimen. The Rapid ONE product line consists of single drug tests, each of which tests for the presence or absence of a single drug of abuse in a urine specimen. The RDS InCup is a POCT product that detects the presence or absence of 1 to 12 DOA in a single urine specimen. The POCT products for oral fluid-based DOA testing include OralStat.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,